Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761657 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT00761657 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 117 participants.
The verdict
NCT00761657, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety, tolerability, and pharmacodynamic effects of different oral doses of roxadustat administered 2 times a week (BIW) or 3 times a week (TIW) for up to 4 weeks to participants with chronic kidney disease (CKD) not requiring dialysis.
Interventions
- DRUG Placebo
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2010-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761657
The ClinicalTrials.gov registry entry for NCT00761657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00761657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00761657 about?
NCT00761657 is a clinical study titled "Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis". The primary objective of the study is to evaluate the safety, tolerability, and pharmacodynamic effects of different oral doses of roxadustat administered 2 times a week (BIW) or 3 times a week (TIW) for up to 4 weeks to participants with chronic kidney disease (CKD) not requiring dialysis.
What is the current status of trial NCT00761657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2006-11-01. Estimated completion is 2010-06-21.
What interventions are being tested in trial NCT00761657?
The interventions under investigation include: Placebo (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT00761657?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.